Novel piperazine derivative PMS1339 exhibits tri-functional properties and cognitive improvement in mice

International Journal of Neuropsychopharmacology

Volumn 12, Issue 10, 2009, Pages 1409-1419

  Miezan Ezoulin, Jean Marc ^a,b   Shao, Bi Yun ^a   Xia, Zheng ^a   Xie, Qiong ^c   Li, Juan ^a   Cui, Yong Yao ^a   Wang, Hao ^a   Dong, Chang Zhi ^b   Zhao, Yan Xing ^a   Massicot, France ^d   Qiu, Zhui Bai ^c   Heymans, Françoise ^b   Chen, Hong Zhuan ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b Laboratoire de Pharmacochimie   (France)

^c FUDAN UNIVERSITY   (China)

^d UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

AChE inhibitor; Alzheimer's disease; amyloid ; PAF antagonist; PMS1339

Indexed keywords

ACETYLCHOLINESTERASE; AMYLOID BETA PROTEIN; CHOLINESTERASE; PIPERAZINE DERIVATIVE; PMS 1339; SCOPOLAMINE; UNCLASSIFIED DRUG; CHOLINESTERASE INHIBITOR; PIPERAZINE; PMS1339;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHOLINERGIC ACTIVITY; CHOLINERGIC NERVE CELL; COGNITION; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG ACTIVITY; DRUG PROTEIN BINDING; ENZYME ACTIVE SITE; ENZYME INHIBITION; ENZYME KINETICS; FLUOROMETRY; IC 50; IN VIVO STUDY; MALE; MEMORY DISORDER; MOLECULAR DOCKING; MOUSE; NONHUMAN; PRIORITY JOURNAL; RABBIT; THROMBOCYTE AGGREGATION; THROMBOCYTE AGGREGATION INHIBITION; TORPEDO CALIFORNICA; ANIMAL; CHEMISTRY; COGNITIVE DEFECT; COMPARATIVE STUDY; DRUG DELIVERY SYSTEM; DRUG EFFECT; ELECTROPHORUS; ENZYMOLOGY; HUMAN; MEMORY; METABOLISM; PHYSIOLOGY; TUMOR CELL LINE;

ACETYLCHOLINESTERASE; ANIMALS; CELL LINE, TUMOR; CHOLINESTERASE INHIBITORS; COGNITION; COGNITION DISORDERS; DRUG DELIVERY SYSTEMS; ELECTROPHORUS; HUMANS; MALE; MEMORY; MICE; PIPERAZINES; RABBITS;

EID: 77954042996     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145709000455     Document Type: Article

References (46)

1. Bartolini M, Bertucci C, Cavrini V, Andrisano V (2003). Beta-amyloid aggregation induced by human acetylcholinesterase : inhibition studies. Biochemical Pharmacology 65, 407-416. (Pubitemid 36084557)
2. Bate C, Kempster S, Williams A (2006). Platelet-activating factor antagonists protect amyloid-b damaged neurons from microglia-mediated death. Neuropharmacology 20, 1-9.
3. Bate C, Salmona M, Williams A (2004). The role of platelet activating factor in prion and amyloid-b neurotoxicity. Neuroreport 15, 509-513. (Pubitemid 38328150)
4. Bazan NG, Colangelo V, Lukiw WJ (2002). Prostaglandins and other lipid mediators in Alzheimer's disease. Prostaglandins & Other Lipid Mediators 68-69, 197-210. (Pubitemid 35247397)
5. Berman HM, Westbrook J, Feng Z, Gilliland G, et al. (2000). The Protein Data Bank. Nucleic Acids Research 28, 235-242. (Pubitemid 30047768)
6. Born GV, Cross MJ (1963). The aggregation of blood platelets. Journal of Physiology 168, 178-195.
7. Bulger EM, Arbabi S, Garcia I, Maier RV (2002). The macrophage response to endotoxin requires platelet activating factor. Shock 17, 173-179.
8. Castro A, Martinez A (2006). Targeting beta-amyloid pathogenesis through acetylcholinesterase inhibitors. Current Pharmaceutical Design 12, 4377-4387. (Pubitemid 44718295)
9. Darvesh S, McDonald RS, Darvesh KV, Mataija D, et al. (2007). Selective reversible inhibition of human butyrylcholinesterase by aryl amide derivatives of phenothiazine. Bioorganic & Medicinal Chemistry 15, 6367-6378. (Pubitemid 47212737)
10. Eikelenboom P, Veerhuis R, Scheper W, Rozemuller AJ, et al. (2006). The significance of neuroinflammation in understanding Alzheimer's disease. Journal of Neural Transmission 113, 1685-1695. (Pubitemid 44657664)
11. Ellman GL, Courtney KD, Andres Jr. V, Feather-Stone RM (1961). A new and rapid colorimetric determination of acetylcholinesterase activity. Biochemical Pharmacology 7, 88-95.
12. Engelberts I, von Asmuth EJ, van der Linden CJ, Buurman WA (1991). The interrelation between TNF, IL-6, and PAF secretion induced by LPS in an in vivo and in vitro murine model. Lymphokine and Cytokine Research 10, 127-131.
13. Eskander MF, Nagykery NG, Leung EY, Khelghati B, Geula C (2005). Rivastigmine is a potent inhibitor of acetyl- and butyrylcholinesterase in Alzheimer's plaques and tangles. Brain Research 1060, 144-152. (Pubitemid 41483599)
14. Ezoulin MJ, Li J, Wu G, Dong CZ, et al. (2005). Differential effect of PMS777, a new type of acetylcholinesterase inhibitor, and galanthamine on oxidative injury induced in human neuroblastoma SK-N-SH cells. Neuroscience Letters 389, 61-65. (Pubitemid 41242886)
15. Garcia-Alloza M, Borrelli LA, Hyman BT, Bacskai BJ (2009). Antioxidants have a rapid and long-lasting effect on neuritic abnormalities in APP: PS1 mice. Neurobiology of Aging. Published online : 4 January 2009. doi:10.1016/ j.neurobiolaging.2008.11.006.
16. Giacobini E (2003). Cholinesterases : new roles in brain function and in Alzheimer's disease. Neurochemical Research 28, 515-522. (Pubitemid 36314842)
17. Greig NH, Utsuki T, Ingram DK, Wang Y, et al. (2005). Selective butyrylcholinesterase inhibition elevates brain acetylcholine, augments learning and lowers Alzheimer beta-amyloid peptide in rodent. Proceedings of the National Academy of Sciences USA 102, 17213-17228.
18. Heneka MT, O'Banion MK (2007). Inflammatory processes in Alzheimer's disease. Journal of Neuroimmunology 184, 69-91. (Pubitemid 46365992)
19. Hershkowitz M, Adunsky A (1996). Binding of plateletactivating factor to platelets of Alzheimer's disease and multiinfarct dementia patients. Neurobiology of Aging 17, 865-868. (Pubitemid 27022739)
20. Inestrosa NC, Dinamarca MC, Alvarez A (2008). Amyloid-cholinesterase interactions : implications for Alzheimer's disease. FEBS Journal 275, 625-632. (Pubitemid 351160969)
21. Jones G, Willett P, Glen RC, Leach AR, Taylor R (1997). Development and validation of a genetic algorithm for flexible docking. Journal of Molecular Biology 267, 727-748. (Pubitemid 27170693)
22. Kamal MA, Klein P, Luo W, Li Y, et al. (2008). Kinetics of human serum Butyrylcholinesterase inhibition by a novel experimental Alzheimer therapeutic, Dihydrobenzodioxepine Cymserine. Neurochemical Research 33, 745-753.
23. Kanowski S, Hoerr R (2003). Ginkgo biloba extract EGb 761 in dementia: intent-to-treat analyses of a 24-week, multi-center, double-blind, placebo-controlled, randomized trial. Pharmacopsychiatry 36, 297-303. (Pubitemid 38085148)
24. Kryger G, Silman I, Sussman JL (1999). Structure of acetylcholinesterase complexed with E2020 (Aricept) : implications for the design of new anti-Alzheimer drugs. Structure 7, 297-307. (Pubitemid 29159689)
25. Kwon YE, Park JY, No KT, Shin JH, et al. (2007). Synthesis, in vitro assay, and molecular modeling of new piperidine derivatives having dual inhibitory potency against acetylcholinesterase and Abeta1-42 aggregation for Alzheimer's disease therapeutics. Bioorganic & Medicinal Chemistry 15, 6596-6607. (Pubitemid 47302310)
26. Landmark K, Reikvam A (2008). Cholinesterase inhibitors in the treatment of dementia : are they useful in clinical practice? Tidsskrift for den Norske Legeforening 128, 294-297.
27. Le Texier L, Favre E, Ronzani N, Massicot F, et al. (1996). Structure-activity relationships in platelet-activating factor (PAF). 8. Tetrahydrofuran derivatives as dual PAF antagonists and acetylcholinesterase inhibitors : anti-acetylcholinesterase activity and comparative SAR. Journal of Lipid Mediators and Cell Signalling 13, 207-222. (Pubitemid 26186283)
28. Li J, Huang H, Miezan Ezoulin JM, Gao XL, et al. (2006). Pharmacological profile of PMS777, a new AChE inhibitor with PAF antagonistic activity. International Journal of Neuropsychopharmacology 10, 21-29. (Pubitemid 46122749)
29. Liston DR, Nielsen JA, Villalobos A, Chapin D, et al. (2004). Pharmacology of selective acetylcholinesterase inhibitors : implications for use in Alzheimer's disease. European Journal of Pharmacology 486, 9-17. (Pubitemid 38130155)
30. Lo CJ, Cryer HG, Fu M, Kim B (1997). Endotoxin-induced macrophage gene expression depends on plateletactivating factor. Archives of Surgery 132, 1342-1347. (Pubitemid 28007167)
31. Mazza M, Capuano A, Bria P, Mazza S (2006). Ginkgo biloba and donepezil: a comparison in the treatment of Alzheimer's dementia in a randomized placebo-controlled double-blind study. European Journal of Neurology 13, 981-985. (Pubitemid 44284905)
32. Onor ML, Trevisiol M, Aguglia E (2007). Rivastigmine in the treatment of Alzheimer's disease : an update. Clinical Interventions in Aging 2, 17-32.
33. Raina P, Santaguida P, Ismaila A, Patterson C, et al. (2008). Effectiveness of cholinesterase inhibitors and memantine for treating dementia : evidence review for a clinical practice guideline. Annals of Internal Medecine 148, 379-397. (Pubitemid 351665469)
34. Ramassamy C, Longpre´ F, Christen Y (2007). Ginkgo biloba extract (EGb 761) in Alzheimer's disease : is there any evidence? Current Alzheimer Research 4, 253-262. (Pubitemid 47025423)
35. Rodriguez-Franco MI, Fernandez-Bachiller MI, Perez C, Hernandez-Ledesma B, Bartolome B (2006). Novel tacrine-melatonin hybrids as dual-acting drugs for Alzheimer disease, with improved acetylcholinesterase inhibitory and antioxidant properties. Journal of Medical Chemical 49, 459-462. (Pubitemid 43157478)
36. Rosini M, Andrisano V, Bartolini M, Bolognesi ML, et al. (2005). Rational approach to discover multipotent anti-Alzheimer drugs. Journal of Medicinal Chemistry 48, 360-363. (Pubitemid 40139781)
37. Rosini M, Simoni E, Bartolini M, Cavalli A, et al. (2008). Inhibition of acetylcholinesterase, beta-amyloid aggregation, and NMDA receptors in Alzheimer's disease : a promising direction for the multi-target-directed ligands gold rush. Journal of Medicinal Chemistry 51, 4381-4384.
38. Shen CL, Murphy RM (1995). Solvent effects on selfassembly of beta-amyloid peptide. Biophysical Journal 69, 640-651.
39. Silman I, Sussman JL (2005). Acetylcholinesterase : ' classical' and 'non-classical ' functions and pharmacology. Current Opinion in Pharmacology 5, 293-302. (Pubitemid 40674253)
40. Snyder SW, Ladror US, Wade WS, Wang GT, et al. (1994). Amyloid-beta aggregation: selective inhibition of aggregation in mixtures of amyloid with different chain lengths. Biophysical Journal 67, 1216-1228.
41. Terry Jr. AV (2001). Spatial navigational (water maze) tasks. In : Buccafusco JJ (Ed.), Methods of Behaviour Analysis in Neuroscience (pp. 148-161). Boca Raton: CRC Press.
42. Uryu S, Tokuhiro S, Murasugi T, Oda T (2002). A novel compound, RS-1178, specifically inhibits neuronal cell death mediated by beta-amyloid-induced macrophage activation in vitro. Brain Research 946, 298-306. (Pubitemid 34876343)
43. Walsh DM, Selkoe DJ (2004). Deciphering the molecular basis of memory failure in Alzheimer's disease. Neuron 44, 181-193. (Pubitemid 39348839)
44. Wang R, Lai L, Wang S (2002). Further development and validation of empirical scoring functions for structure-based binding affinity prediction. Journal of Computer-Aided Molecular Design 16, 11-26. (Pubitemid 34855041)
45. Yao Y, Chinnici C, Tang H, Trojanowski JQ, et al. (2004). Brain inflammation and oxidative stress in a transgenic mouse model of Alzheimer-like brain amyloidosis. Journal of Neuroinflammation 1, 21.
46. Zhu Y, Xiao K, Ma L, Xiong B, et al. (2009). Design, synthesis and biological evaluation of novel dual inhibitors of acetylcholinesterase and beta-secretase. Bioorganic & Medicinal Chemistry. Published online : 6 January 2009. doi :10.1016/ j.bmc.2008.12.067.